|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Immunosuppression for in vivo research: state-of-the-at protocols and experimental approaches显示文摘几乎,用非自体同源的房间,织物或机关移植的每试验性的治疗策略在临床的翻译前在小、大的动物模型被测试。因为这些策略在大多数情况中要求免疫力的抑制,抑制免疫力的协议是在移植实验的一个关键元素。然而,没有详细知识,标准抑制免疫力的协议经常在特别试验性的背景以内并且在选择模型种类关于他们的功效被使用。如此的协议的优化对到人的病人的试验性的结果的翻译恰当,因此,保证推进调查。这评论与种类特定的药 metabolization 和副作用的考虑关于抑制免疫力的药类以及他们的剂量和应用程序政体总结当前的知识。它也总结新奇 immunomodulatory 策略的当代的知识,例如间充质的干细胞或抗体的使用。因此,这评论被打算用作一个最先进的概要让研究人员精制应用试验性的免疫力的抑制和 immunomodulation 策略提高现出症状之前的潜的移植研究的预兆的价值。 | Rita Diehl Fabienne Ferrara Claudia Müller Antje Y Dreyer Damian D McLeod Stephan Fricke Johannes Boltze | 2017 | Cellular & Molecular Immunology2017，14，2： | 5 |
| 2 | Percutaneous radiofrequency ablation for early hepatocellular carcinoma: Risk factors for survival显示文摘AIM: To evaluate outcomes of radiofrequency ablation(RFA) therapy for early hepatocellular carcinoma(HCC) and identify survival- and recurrence-related factors. METHODS: Consecutive patients diagnosed with early HCC by computed tomography(CT) or magnetic resonance imaging(MRI)(single nodule of ≤ 5 cm, or multi-(up to 3) nodules of ≤ 3 cm each) and who underwent RFA treatment with curative intent between January 2010 and August 2011 at the Instituto do Cancer do Estado de S o Paulo, Brazil were enrolled in the study. RFA of the liver tumors(with 1.0 cm ablative margin) was carried out under CT-fluoro scan and ultrasonic image guidance of the percutaneous ablation probes. Procedure-related complications were recorded. At 1-mo post-RFA and 3-mo intervals thereafter, CT and MRI were performed to assess outcomes of complete response(absence of enhancing tissue at the tumor site) or incomplete response(enhancing tissue remaining at the tumor site). Overall survival and diseasefree survival rates were estimated by the Kaplan-Meier method and compared by the log rank test or simple Cox regression. The effect of risk factors on survival was assessed by the Cox proportional hazard model. RESULTS: A total of 38 RFA sessions were performed during the study period on 34 patients(age in years: mean, 63 and range, 49-84). The mean follow-up time was 22 mo(range, 1-33). The study population showed predominance of male sex(76%), less severe liver disease(Child-Pugh A, n = 26; Child-Pugh B, n = 8), and single tumor(65%). The maximum tumor diameters ranged from 10 to 50 mm(median, 26 mm). The initial(immediately post-procedure) rate of RFAinduced complete tumor necrosis was 90%. The probability of achieving complete response was significantly greater in patients with a single nodule(vs patients with multi-nodules, P = 0.04). Two patients experienced major complications, including acute pulmonary edema(resolved with intervention) and intestinal perforation(led to death). The 1- and 2-year overall survival rates were 82% and 71%, respectively. Sex, tumor size, initial response, and recurrence status influenced survival, but did not reach the threshold of statistical significance. Child-Pugh class and the model for end-stage liver disease score were identified as predictors of survival by simple Cox regression, but only Child-Pugh class showed a statistically significant association to survival in multiple Cox regression analysis(HR = 15; 95%CI: 3-76 mo; P = 0.001). The 1-and 2-year cumulative disease-free survival rates were 65% and 36%, respectively. CONCLUSION: RFA is an effective therapy for local tumor control of early HCC, and patients with preserved liver function are the best candidates. | Luciana Kikuchi Marcos Menezes Aline L Chagas Claudia M Tani Regiane SSM Alencar Marcio A Diniz Venncio AF Alves Luiz Augusto Carneiro D’Albuquerque Flair José Carrilho | 2014 | World Journal of Gastroenterology2014，20，6： | 5 |
| 3 | Fatty liver disease,an emerging etiology of hepatocellular carcinoma in Argentina显示文摘AIM To investigate any changing trends in the etiologies of hepatocellular carcinoma(HCC) in Argentina during the last years. METHODS A longitudinal cohort study was conducted by 14 regional hospitals starting in 2009 through 2016. All adult patients with newly diagnosed HCC either with pathology or imaging criteria were included. Patients were classified as presenting non-alcoholic fatty liver disease(NAFLD) either by histology or clinically, provided that all other etiologies of liver disease were ruled out, fatty liver was present on abdominal ultrasound and alcohol consumption was excluded. Complete follow-up was assessed in all included subjects since the date of HCC diagnosis until death or last medical visit.RESULTS A total of 708 consecutive adults with HCC were included. Six out of 14 hospitals were liver transplant centers(n = 484). The prevalence of diabetes mellitus was 27.7%. Overall, HCV was the main cause of liver disease related with HCC(37%) including cirrhotic and non-cirrhotic patients, followed by alcoholic liver disease 20.8%, NAFLD 11.4%, cryptogenic 9.6%, HBV 5.4% infection, cholestatic disease and autoimmune hepatitis 2.2%, and other causes 9.9%. A 6-fold increase in the percentage corresponding to NAFLDHCC was detected when the starting year, i.e., 2009 was compared to the last one, i.e., 2015(4.3% vs 25.6%; P < 0.0001). Accordingly, a higher prevalence of diabetes mellitus was present in NAFLD-HCC group 61.7% when compared to other than NAFLD-HCC 23.3%(P < 0.0001). Lower median AFP values at HCC diagnosis were observed between NAFLD-HCC and non-NAFLD groups(6.6 ng/m L vs 26 ng/m L; P = 0.02). Neither NAFLD nor other HCC etiologies were associated with higher mortality.CONCLUSION The growing incidence of NAFLD-HCC documented in the United States and Europe is also observed in Argentina, a confirmation with important Public Health implications. | Federico Pinero Josefina Pages Sebastián Marciano Nora Fernández Jorge Silva Margarita Anders Alina Zerega Ezequiel Ridruejo Beatriz Ameigeiras Claudia D’Amico Luis Gaite Carla Bermúdez Manuel Cobos Carlos Rosales Gustavo Romero Lucas McCormack Virginia Reggiardo Luis Colombato Adrián Gadano Marcelo Silva | 2018 | World Journal of Hepatology2018，10，1： | 4 |
| 4 | Tumor microenvironment involvement in colorectal cancer progression via Wnt/β-catenin pathway:Providing understanding of the complex mechanisms of chemoresistance显示文摘Colorectal cancer(CRC)continues to be one of the main causes of death from cancer because patients progress unfavorably due to resistance to current therapies.Dysregulation of the Wnt/β-catenin pathway plays a fundamental role in the genesis and progression of several types of cancer,including CRC.In many subtypes of CRC,hyperactivation of theβ-catenin pathway is associated with mutations of the adenomatous polyposis coli gene.However,it can also be associated with other causes.In recent years,studies of the tumor microenvironment(TME)have demonstrated its importance in the development and progression of CRC.In this tumor nest,several cell types,structures,and biomolecules interact with neoplastic cells to pave the way for the spread of the disease.Cross-communications between tumor cells and the TME are then established primarily through paracrine factors,which trigger the activation of numerous signaling pathways.Crucial advances in the field of oncology have been made in the last decade.This Minireview aims to actualize what is known about the central role of the Wnt/β-catenin pathway in CRC chemoresistance and aggressiveness,focusing on crosscommunication between CRC cells and the TME.Through this analysis,our main objective was to increase the understanding of this complex disease considering a more global context.Since many treatments for advanced CRC fail due to mechanisms involving chemoresistance,the data here exposed and analyzed are of great interest for the development of novel and effective therapies. | María Belén Novoa Díaz María Julia Martín Claudia Gentili | 2022 | World Journal of Gastroenterology2022，28，26： | 3 |
| 5 | Intermediate-advanced hepatocellular carcinoma in Argentina:Treatment and survival analysis显示文摘BACKGROUND Hepatocellular carcinoma(HCC) represents the sixteenth most frequent cancer in Argentina. The rise of new therapeutic modalities in intermediate-advanced HCC opens up a new paradigm for the treatment of HCC.AIM To describe real-life treatments performed in patients with intermediateadvanced HCC before the approval of new systemic options.METHODS This longitudinal observational cohort study was conducted between 2009 and2016 in 14 different regional hospitals from Argentina. Included subjects had intermediate-advanced Barcelona Clinic Liver Cancer(BCLC) HCC stages(BCLC B to D). Primary end point analyzed was survival, which was assessed for each BCLC stage from the date of treatment until last patient follow-up or death.Kaplan Meier survival curves and Cox regression analysis were performed, with hazard ratios(HR) calculations and 95% confidence intervals(95%CI).RESULTS From 327 HCC patients, 41% were BCLC stage B, 20% stage C and 39% stage D.Corresponding median survival were 15 mo(IQR 5-26 mo), 5 mo(IQR 2-13 mo)and 3 mo(IQR 1-13 mo)(P < 0.0001), respectively. Among BCLC-B patients(n =135), 57% received TACE with a median number of 2 sessions(IQR 1-3 sessions).Survival was significantly better in BCLC-B patients treated with TACE HR =0.29(CI: 0.21-0.40) than those without TACE. After tumor reassessment by RECIST 1.1 criteria following the first TACE, patients with complete response achieved longer survival (HR = 0.15(CI: 0.04-0.56, P = 0.005))Eighty-two patients were treated with sorafenib, mostly BCLC-B and C(87.8%). However,12.2% were BCLC-D. Median survival with sorafenib was 4.5 mo(IQR 2.3-11.7 mo);which was lower among BCLC-D patients 3.2 mo(IQR 2.0-14.1 mo). A total of 36 BCLC-B patients presented tumor progression after TACE. In these patients,treatment with sorafenib presented better survival when compared to those patients who received sorafenib without prior TACE [HR = 0.26(CI: 0.09-0.71);P= 0.013].CONCLUSION In this real setting, our results were lower than expected. This highlights unmet needs in Argentina, prior to the introduction of new treatments for HCC. | Federico Pinero Sebastián Marciano Nora Fernández Jorge Silva Margarita Anders Alina Zerega Ezequiel Ridruejo Gustavo Romero Beatriz Ameigeiras Claudia D’Amico Luis Gaite Carla Bermúdez Virginia Reggiardo Luis Colombato Adrián Gadano Marcelo Silva | 2019 | World Journal of Gastroenterology2019，25，27： | 3 |
| 6 | Emergence of novel strains of avian infectious bronchitis virus in Sweden显示文摘 | Shahid Hussain Abro Lena H.M. Renstr?m Karin Ullman Mats Isaksson Siamak Zohari Désirée S. Jansson Sándor Belák Claudia Baule | 2011 | Veterinary Microbiology (-)2011，，2： | 2 |
| 7 | Long-term survival of patients with stage Ⅱ and Ⅲgastric cancer who underwent gastrectomy with inadequate nodal assessment显示文摘BACKGROUND Gastric cancer is an aggressive disease with frequent lymph node(LN)involvement.The NCCN recommends a D2 lymphadenectomy and the harvesting of at least 16 LNs.This threshold has been the subject of great debate,not only for the extent of surgery but also for more appropriate staging.The reclassification of stage IIB through IIIC based on N3b nodal staging in the eighth edition of the American Joint Committee on Cancer(AJCC)staging system highlights the efforts to more accurately discriminate survival expectancy based on nodal number.Furthermore,studies have suggested that pathologic assessment of 30 or more LNs improve prognostic accuracy and is required for proper staging of gastriccancer.AIM To evaluate the long-term survival of advanced gastric cancer patients who deviated from expected survival curves because of inadequate nodal evaluation.METHODS Eligible patients were identified from the Surveillance,Epidemiology,and End Results database.Those with stage II-III gastric cancer were considered for inclusion.Three groups were compared based on the number of analyzed LNs.They were inadequate LN assessment(ILA,<16 LNs),adequate LN assessment(ALA,16-29 LNs),and optimal LN assessment(OLA,≥30 LNs).The main outcomes were overall survival(OS)and cancer-specific survival.Data were analyzed by the Kaplan-Meier product-limit method,log-rank test,hazard risk,and Cox proportional univariate and multivariate models.Propensity score matching(PSM)was used to compare the ALA and OLA groups.RESULTS The analysis included 11607 patients.Most had advanced T stages(T3=48%;T4=42%).The pathological AJCC stage distribution was IIA=22%,IIB=18%,IIIA=26%,IIIB=22%,and IIIC=12%.The overall sample divided by the study objective included ILA(50%),ALA(35%),and OLA(15%).Median OS was 24 mo for the ILA group,29 mo for the ALA group,and 34 mo for the OLA group(P<0.001).Univariate analysis showed that the ALA and OLA groups had better OS than the ILA group[ALA hazard ratio(HR)=0.84,95%confidence interval(CI):0.79-0.88,P<0.001 and OLA HR=0.73,95%CI:0.68-0.79,P<0.001].The OS outcome was confirmed by multivariate analysis(ALA HR=0.68,95%CI:0.64-0.71,P<0.001 and OLA:HR=0.48,95%CI:0.44-0.52,P<0.001).A 1:1 PSM analysis in 3428 patients found that the OLA group had better survival than the ALA group(OS:OLA median=34 mo vs ALA median=26 mo,P<0.001,which was confirmed by univariate analysis(HR=0.81,95%CI:0.75-0.89,P<0.001)and multivariate analysis:(HR=0.71,95%CI:0.65-0.78,P<0.001).CONCLUSION Proper nodal staging is a critical issue in gastric cancer.Assessment of an inadequate number of LNs places patients at high risk of adverse long-term survival outcomes. | Jacopo Desiderio Andrea Sagnotta Irene Terrenato Eleonora Garofoli Claudia Mosillo Stefano Trastulli Federica Arteritano Federico Tozzi Vito D'Andrea Yuman Fong Yanghee Woo Sergio Bracarda Amilcare Parisi | 2021 | World Journal of Gastrointestinal Surgery2021，13，11： | 2 |
| 8 | Human natural killer cell receptor:insights into their molecular function and structure显示文摘 | Biassoni R Claudia C Marras D | 2003 | J Cell Mol Med2003，7，4： | 1 |
| 9 | Genetic influ- ences of adiponectin on insulin resistance, type 2 dia- betes, and cardiovascular disease显示文摘 | Claudia M Vincenzo T Alessandro D | 2007 | Diabetes2007，56，： | 1 |
| 10 | Detection of Paenibacillus larvae subspecies larvae spores in naturally infected bee larvae and artificially contaminated honey by PCR显示文摘 | Claudia Piccini Bruno D’Alessandro Karina Antúnez Pablo Zunino | 2002 | World Journal of Microbiology and Biotechnology2002，，8： | 1 |
| 11 | A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome显示文摘 | Claudia M Tonino E Rosa D P | 2002 | Diabetes2002，51，7： | 1 |
| 12 | The impact of eHealth on the quality and safety of health care : a systematic overview 显示文摘 | Black A D Josip C Claudia P | 2011 | Plos Medicine2011，8，10： | 1 |
| 13 | Removal of Mn from aqueous solution using fly ash and its hydrothermal synthetic zeolite 显示文摘 | Claudia B Franceseo C Spartaco D G | 2014 | Journal of Environmental Management2014，137，1： | 1 |
| 14 | Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes显示文摘 | Raghu Kadaba Hanna Birke Jun Wang Steven Hooper Claudia D Andl Francesco Di Maggio Erdinc Soylu Mohammed Ghallab Daniel Bor Fieke EM Froeling Satyajit Bhattacharya Anil K Rustgi Erik Sahai Claude Chelala Peter Sasieni Hemant M Kocher | 2013 | J. Pathol2013，，1： | 1 |
| 15 | Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-1 显示文摘 | THOMAS M KATJA D CLAUDIA W | 1993 | European Journal of Immunology1993，23，7： | 1 |
| 16 | An ionic liquid as a solvent for headspace single drop microextraction of ehlorobenzenes from water samples显示文摘 | Lorena V Elefteria P Claudia E D | | 0，，01： | 1 |
| 17 | Gamma interferon release assays for detection of Mycobacterium tuberculosis in- fection显示文摘 | Pai M Claudia M D Sandra V K | 2014 | Clin Microbiol Rev2014，7，1： | 1 |
| 18 | Asymmetric Cyclization of 2' -Hydroxychalcones to Flavanones: Catalysis by Ch-Iral Bronsted Acids and Bases显示文摘 | CLAUDIA D GERHARD R LUKAS H | 2007 | Eur J Org Chem2007，，1： | 1 |
| 19 | Specific functions of individual class Ⅲ peroxidase genes显示文摘 | Claudia C Chfistophe D | 2009 | Journal of Experimental Botany2009，60，2： | 1 |
| 20 | Lipotoxicity: Effects of Dietary Saturated and Transfatty Acids显示文摘 | Débora Estadella Claudia M. da Penha Oller do Nascimento Lila M. Oyama Eliane B. Ribeiro Ana R. Damaso Aline de Piano Fábio Santos Lira | 2013 | Mediators of Inflammation2013，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员